A good GIF.
The Study: The HannaH trial was designed to see if subcutaneous trastuzumab is equally safe and effective, all while requiring no more time than it takes to enjoy a friendly GIF. All patients received neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab. The initial 2012 publication reported that the primary endpoints of pathologic complete response rate (40-45%) and serum concentrations were similar. This final report now compares survival outcomes and long-term effects. As expected based on path response, there were no differences in the rates of event free (65%) and overall (84%) survival at 6 years. Neither were there differences in rates of toxicity. As one would expect, close to 90% of patients (minus Price is Right fans) prefer the subQ formulation, approved by the FDA under the trade name Herceptin Hylecta back in February. Serendipitously, this subQ formulation hits the market along with a number of infused trastuzumab biosimilars.
Bottom Line: Subcutaneous trastuzumab appears to be just as safe and effective as intravenous trastuzumab while being way more convenient. | Jackisch, JAMA Oncol 2019